Does SummaCare Cover Rogaine?

What Is Rogaine and Why Does Coverage Get Complicated?

Rogaine is the brand name for topical minoxidil, a vasodilator first approved by the FDA in 1988 for androgenetic alopecia (pattern hair loss) in men, and later in women. The OTC status of Rogaine is the central reason most health plans, including SummaCare, will not pay for it.

The FDA classifies both the 2% and 5% topical minoxidil formulations as over-the-counter drugs [1]. Under standard insurance law and most plan documents, OTC drugs are treated like groceries: the member pays out-of-pocket unless the plan contains a specific OTC drug benefit rider, which is rare in commercial plans.

How Minoxidil Works

Minoxidil extends the anagen (active growth) phase of hair follicles and widens follicular diameter. The exact molecular mechanism is not fully understood, though potassium-channel opening and local vasodilation are thought to contribute [2]. Applied twice daily, it must be used indefinitely; hair loss resumes within three to six months of stopping treatment [3].

OTC vs. Prescription Minoxidil: A Key Coverage Distinction

The same molecule exists in prescription form. Oral minoxidil tablets (originally approved for hypertension at doses of 10 to 40 mg daily) are used off-label for hair loss at much lower doses, typically 0.625 to 2.5 mg daily for women and 2.5 to 5 mg daily for men [4]. Because oral minoxidil requires a prescription, it sits on pharmacy formularies and may attract insurance reimbursement. Compounded topical minoxidil (for example, a custom 8% or 10% solution) is also prescription-only and may similarly be billable.

This OTC-versus-prescription distinction is where coverage conversations with SummaCare must begin.

SummaCare Plan Types and How They Affect Formulary Access

SummaCare, based in Akron, Ohio, offers several product lines: commercial HMO and PPO plans sold to employers, individual and family plans through the ACA marketplace, Medicare Advantage plans (including Part D drug coverage), and Medicaid-managed care products. Each plan maintains a separate formulary, and coverage rules differ significantly across them.

Commercial HMO and PPO Plans

SummaCare's employer-sponsored commercial plans follow standard commercial drug-benefit design. OTC Rogaine is excluded. Prescription oral minoxidil may appear on Tier 1 (generic) or Tier 2 (preferred brand) depending on the specific plan year's formulary document. Members should download the current Summary of Benefits and Coverage (SBC) or call the member services number on the back of their card to confirm the current tier placement.

Medicare Advantage with Part D

Medicare Part D, which governs drug coverage in Medicare Advantage plans, explicitly excludes drugs used for "cosmetic purposes or hair growth" under 42 CFR 423.100 [5]. The Centers for Medicare and Medicaid Services (CMS) lists hair-growth drugs among the six excluded drug categories that Part D sponsors may not cover [6]. This means SummaCare Medicare Advantage members face a statutory barrier, not just a formulary decision, when seeking coverage for any minoxidil product labeled for hair growth.

There is one narrow exception: if minoxidil is prescribed primarily for hypertension in a Medicare Advantage patient, and the diagnosis on the prescription reflects that indication, some Part D plans may process the claim. This requires precise prescribing and is not guaranteed.

ACA Marketplace Plans

ACA plans must cover the essential health benefits defined by the Affordable Care Act, but hair-loss drugs are not among them [7]. Marketplace SummaCare plans therefore follow the same OTC exclusion as commercial plans. Prescription oral minoxidil coverage depends entirely on whether it appears in the plan's formulary for the benefit year purchased.

Prior Authorization Requirements for Prescription Minoxidil

Even when prescription minoxidil appears on a SummaCare formulary, prior authorization (PA) is the norm rather than the exception for dermatological treatments classified as non-essential or cosmetic-adjacent.

What Prior Authorization Typically Requires

A PA request for prescription minoxidil generally requires:

• A confirmed diagnosis code (L64.9 for androgenic alopecia, or L65.9 for other non-scarring alopecia) [8]
• Documentation that the patient has had a clinical evaluation for secondary causes of hair loss (thyroid disease, iron deficiency, autoimmune disease)
• In some plans, evidence that a 12-week trial of OTC topical minoxidil was attempted and was inadequate or not tolerated
• A letter of medical necessity from the prescribing clinician

The step-therapy requirement (trying OTC first) is particularly common and clinically ironic: the plan may require patients to self-purchase OTC Rogaine before agreeing to cover the prescription alternative. Patients should ask their prescriber to document any reasons that oral minoxidil is specifically preferred (systemic absorption concerns, scalp sensitivity, patient adherence barriers) to support the PA narrative.

Appeals Process

If SummaCare denies a PA request, the member has the right to a first-level internal appeal, followed by an independent external review under the ACA's external appeals provisions [9]. The Ohio Department of Insurance oversees external review for state-regulated plans. Success rates for external appeals in dermatology drug denials run approximately 39 to 54% in published analyses of commercial plan appeals data [10].

Clinical Evidence Supporting Minoxidil Use

Coverage decisions aside, the clinical case for minoxidil in androgenetic alopecia is well-established. Understanding this evidence helps clinicians write stronger prior-authorization letters.

Topical Minoxidil Trials

A randomized controlled trial published in the Journal of the American Academy of Dermatology compared minoxidil 5% topical solution to 2% and to placebo in men with androgenetic alopecia over 48 weeks. The 5% group showed 45% more hair regrowth than the 2% group at 48 weeks, and both active arms significantly outperformed placebo (P<0.001) [11]. Women with Ludwig Grade I or II alopecia showed statistically significant hair count increases with twice-daily 2% topical minoxidil vs. Placebo after 32 weeks in a trial of 256 participants [12].

Oral Minoxidil for Hair Loss

A 2022 systematic review in the Journal of the American Academy of Dermatology analyzed 17 studies of low-dose oral minoxidil for hair loss across multiple alopecia types [13]. Doses of 0.25 to 5 mg daily produced clinically meaningful hair density improvements in 14 of those 17 studies. Adverse events were generally mild and included hypertrichosis (unwanted body hair) and mild fluid retention at doses above 2.5 mg. No serious cardiovascular events were reported at doses below 5 mg in individuals without pre-existing cardiac disease.

Finasteride as a Comparator

For male androgenetic alopecia, oral finasteride 1 mg daily (brand: Propecia) is a well-studied alternative. A two-year randomized trial in 1,553 men found that finasteride produced a mean 10.6% increase in hair count from baseline vs. A 6.6% decrease in the placebo group [14]. SummaCare commercial formularies are more likely to cover generic finasteride than minoxidil, given its prescription-only status and lower acquisition cost. The two drugs target different mechanisms and may be used together under physician supervision.

Combining Minoxidil and Finasteride

A 2021 open-label trial published in Dermatology and Therapy compared topical minoxidil 0.1% plus finasteride 0.25% combination solution (compounded) to minoxidil 5% alone in 90 men over 24 weeks [15]. The combination group showed a 14.3% greater improvement in total hair count at 24 weeks. Compounded combination products require a prescription and may qualify for coverage under specialty pharmacy benefits, though prior authorization criteria are even stricter for compounded drugs under most SummaCare plans.

How to Check Your Specific SummaCare Plan's Coverage

No article can substitute for a direct formulary lookup, because SummaCare updates its drug lists annually and mid-year amendments occur. Here is a reliable step-by-step process:

Step 1. Pull the Current Formulary Document

Log in to the SummaCare member portal and download the current-year formulary PDF. Search for "minoxidil" in the document. Note the tier number, any PA flags, and any quantity limits.

Step 2. Call Member Services with Specific Questions

The number is on the back of your insurance card. Ask:

• "Is oral minoxidil [NDC number from your pharmacy] covered under my plan's drug benefit?"
• "Is prior authorization required, and what criteria must be met?"
• "Is there a step-therapy requirement for OTC minoxidil first?"

Write down the representative's name and the call reference number.

Step 3. Obtain a Prescription and Submit a PA

Ask your dermatologist or primary care clinician to submit the PA with the correct diagnosis code and a medical necessity letter. The American Academy of Dermatology has published guidance on documenting alopecia for insurance purposes that clinicians can use as a template [16].

Step 4. Explore the Pharmacy Benefit vs. Medical Benefit

Some injectable or in-office hair-loss procedures (platelet-rich plasma, for example) may be billed under the medical benefit rather than the pharmacy benefit. Oral and topical minoxidil are always pharmacy claims. Clarify which benefit applies before submitting.

Costs Without Insurance Coverage

If SummaCare does not cover Rogaine or prescription minoxidil, out-of-pocket costs vary considerably by product choice.

| Product | Typical Monthly Cost (OOP) | |---|---| | Rogaine 5% foam (OTC, brand) | $30, $50 | | Generic topical minoxidil 5% solution | $10, $20 | | Oral minoxidil 2.5 mg tablets (generic) | $10, $30 | | Oral finasteride 1 mg (generic) | $15, $30 | | Compounded topical minoxidil/finasteride | $60, $120 |

GoodRx, Mark Cuban's Cost Plus Drugs, and Amazon Pharmacy offer generic oral minoxidil tablets at prices that can be lower than most copays. A 90-day supply of generic oral minoxidil 2.5 mg tablets costs approximately $25, $45 at Cost Plus Drugs as of early 2025 [17]. For many patients, paying out-of-pocket for generic oral minoxidil is more practical than navigating a complex PA process for a $15 copay on a $20 drug.

Alternatives That SummaCare Is More Likely to Cover

Certain hair-loss treatments carry better coverage odds because they are prescription-only with established medical billing pathways.

Oral Finasteride

Generic finasteride 1 mg appears on many commercial formularies as a Tier 1 generic. It is FDA-approved specifically for male androgenetic alopecia [18]. Women of childbearing potential cannot use finasteride due to teratogenicity risk, and it carries a black-box warning for that reason [19].

Dutasteride (Off-Label)

Dutasteride 0.5 mg inhibits both type 1 and type 2 5-alpha-reductase, vs. Finasteride's type 2 selectivity. A randomized trial of 917 Korean men found dutasteride 0.5 mg produced statistically greater hair count improvement than finasteride 1 mg at 24 weeks (P<0.001) [20]. Dutasteride is not FDA-approved for hair loss in the United States, so PA approval is harder to obtain, but the generic price is low enough that self-pay is feasible.

Spironolactone for Women

For women with androgenetic alopecia or alopecia associated with polycystic ovary syndrome (PCOS), spironolactone 50 to 200 mg daily is a common off-label treatment. Generic spironolactone is inexpensive and generally Tier 1 on most formularies. A retrospective cohort study of 98 women found that 74.5% reported subjective hair density improvement after six months of spironolactone at doses of 100 to 200 mg [21].

What Dermatologists Say About Insurance and Hair Loss Treatment

The American Academy of Dermatology Position Statement on Alopecia states that androgenetic alopecia affects approximately 50% of men by age 50 and up to 40% of women by age 70, making it one of the most prevalent dermatological conditions in the United States [22]. Despite this prevalence, coverage remains inconsistent because the condition has historically been classified as cosmetic rather than medical.

"Androgenetic alopecia has real psychological consequences, including documented associations with depression and reduced quality of life," notes guidance from the International Society of Hair Restoration Surgery clinical practice guidelines. "The cosmetic designation does not reflect the clinical burden on patients." [23]

The AAD recommends that clinicians document the psychological and functional impact of hair loss when submitting prior authorization requests, specifically citing validated tools such as the Hair-Specific Skindex-29 or the Dermatology Life Quality Index (DLQI) to support medical necessity arguments [22].

Special Situations: SummaCare and Hair Loss Secondary to Medical Conditions

Hair loss is not always androgenetic. When alopecia results from a covered medical condition, the coverage calculus changes.

Alopecia Areata

SummaCare Medicare Advantage and commercial plans may cover baricitinib (Olumiant) or ritlecitinib (Litfulo), both FDA-approved for severe alopecia areata. The BRAVE-AA1 and BRAVE-AA2 trials (combined N=1,200) demonstrated that baricitinib 4 mg produced a SALT score of 20 or less (indicating 80% or greater scalp hair coverage) in 35% of patients vs. 5% on placebo at 36 weeks [24]. PA is still required, but a clear FDA indication makes approval far more likely.

Chemotherapy-Induced Alopecia

Scalp cooling (Paxman, Dignicap) is cleared by the FDA for reducing chemotherapy-induced hair loss. Coverage under SummaCare's oncology benefit varies by plan. Oral or topical minoxidil used to accelerate regrowth after chemotherapy falls outside the approved indication, so coverage is unlikely, though some oncologists successfully argue for PA under the reconstructive/restorative benefit category.

Hypothyroid-Associated Hair Loss

If hair loss is documented as a consequence of hypothyroidism, treatment with levothyroxine (a covered Rx) addresses the underlying cause. Minoxidil is generally not indicated in this setting, and SummaCare would be unlikely to approve it for that diagnosis.

Documentation Checklist for Your Prior Authorization Request

Physicians submitting a PA for minoxidil or an alternative hair-loss treatment to SummaCare should include:

• Diagnosis code (ICD-10): L64.0 drug-induced androgenic alopecia, L64.8 other androgenic alopecia, or L64.9 androgenic alopecia unspecified
• Clinical notes documenting duration (typically greater than six months), pattern, and severity using an objective scale such as the Norwood-Hamilton scale for men or the Ludwig scale for women
• Lab work ruling out reversible causes: TSH, ferritin, CBC, and total testosterone or free androgen index if PCOS is suspected [25]
• Statement of inadequate response to or intolerance of OTC topical minoxidil if step therapy applies
• DLQI or equivalent quality-of-life score documenting psychosocial impact [26]
• Photographs taken at standard angles under consistent lighting, which satisfy most plan requirements for objective documentation

A complete, well-organized PA packet submitted on the first attempt reduces the average decision time from 30 days to fewer than 14 days based on industry PA processing benchmarks.